GB202005520D0 - Elastase inhibition - Google Patents

Elastase inhibition

Info

Publication number
GB202005520D0
GB202005520D0 GBGB2005520.8A GB202005520A GB202005520D0 GB 202005520 D0 GB202005520 D0 GB 202005520D0 GB 202005520 A GB202005520 A GB 202005520A GB 202005520 D0 GB202005520 D0 GB 202005520D0
Authority
GB
United Kingdom
Prior art keywords
elastase inhibition
elastase
inhibition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB2005520.8A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mereo Biopharma 3 Ltd
Original Assignee
Mereo Biopharma 3 Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mereo Biopharma 3 Ltd filed Critical Mereo Biopharma 3 Ltd
Priority to GBGB2005520.8A priority Critical patent/GB202005520D0/en
Publication of GB202005520D0 publication Critical patent/GB202005520D0/en
Priority to HRP20231065TT priority patent/HRP20231065T1/en
Priority to EP23187058.5A priority patent/EP4252850A3/en
Priority to HUE21714345A priority patent/HUE064089T2/en
Priority to PCT/GB2021/050653 priority patent/WO2021209739A1/en
Priority to ES21714345T priority patent/ES2962498T3/en
Priority to US17/995,908 priority patent/US20230218596A1/en
Priority to AU2021256835A priority patent/AU2021256835A1/en
Priority to EP21714345.2A priority patent/EP4106757B1/en
Priority to LTEPPCT/GB2021/050653T priority patent/LT4106757T/en
Priority to SI202130071T priority patent/SI4106757T1/en
Priority to PL21714345.2T priority patent/PL4106757T3/en
Priority to US17/995,909 priority patent/US20230190723A1/en
Priority to PT217143452T priority patent/PT4106757T/en
Priority to MX2022012942A priority patent/MX2022012942A/en
Priority to FIEP21714345.2T priority patent/FI4106757T3/en
Priority to IL297211A priority patent/IL297211A/en
Priority to JP2022562608A priority patent/JP2023522010A/en
Priority to DK21714345.2T priority patent/DK4106757T3/en
Priority to PCT/GB2021/050658 priority patent/WO2021209740A1/en
Ceased legal-status Critical Current

Links

GBGB2005520.8A 2020-04-16 2020-04-16 Elastase inhibition Ceased GB202005520D0 (en)

Priority Applications (20)

Application Number Priority Date Filing Date Title
GBGB2005520.8A GB202005520D0 (en) 2020-04-16 2020-04-16 Elastase inhibition
PCT/GB2021/050658 WO2021209740A1 (en) 2020-04-16 2021-03-16 Methods involving neutrophil elastase inhibitor alvelestat for treating coronavirus infection
EP21714345.2A EP4106757B1 (en) 2020-04-16 2021-03-16 Methods involving neutrophil elastase inhibitor alvelestat for treating respiratory disease mediated by alpha-1 antitrypsin deficiency
SI202130071T SI4106757T1 (en) 2020-04-16 2021-03-16 Methods involving neutrophil elastase inhibitor alvelestat for treating respiratory disease mediated by alpha-1 antitrypsin deficiency
HUE21714345A HUE064089T2 (en) 2020-04-16 2021-03-16 Methods involving neutrophil elastase inhibitor alvelestat for treating respiratory disease mediated by alpha-1 antitrypsin deficiency
PCT/GB2021/050653 WO2021209739A1 (en) 2020-04-16 2021-03-16 Methods involving neutrophil elastase inhibitor alvelestat for treating respiratory disease mediated by alpha-1 antitrypsin deficiency
ES21714345T ES2962498T3 (en) 2020-04-16 2021-03-16 Methods involving the neutrophil elastase inhibitor alvelestat for the treatment of respiratory diseases mediated by alpha-1 antitrypsin deficiency
US17/995,908 US20230218596A1 (en) 2020-04-16 2021-03-16 Methods involving neutrophil elastase inhibitor alvelestat for treating coronavirus infection
AU2021256835A AU2021256835A1 (en) 2020-04-16 2021-03-16 Methods involving neutrophil elastase inhibitor alvelestat for treating respiratory disease mediated by alpha-1 antitrypsin deficiency
HRP20231065TT HRP20231065T1 (en) 2020-04-16 2021-03-16 Methods involving neutrophil elastase inhibitor alvelestat for treating respiratory disease mediated by alpha-1 antitrypsin deficiency
LTEPPCT/GB2021/050653T LT4106757T (en) 2020-04-16 2021-03-16 Methods involving neutrophil elastase inhibitor alvelestat for treating respiratory disease mediated by alpha-1 antitrypsin deficiency
EP23187058.5A EP4252850A3 (en) 2020-04-16 2021-03-16 Methods involving neutrophil elastase inhibitor alvelestat for treating respiratory disease mediated by alpha-1 antitrypsin deficiency
PL21714345.2T PL4106757T3 (en) 2020-04-16 2021-03-16 Methods involving neutrophil elastase inhibitor alvelestat for treating respiratory disease mediated by alpha-1 antitrypsin deficiency
US17/995,909 US20230190723A1 (en) 2020-04-16 2021-03-16 Methods involving neutrophil elastase inhibitor alvelestat for treating respiratory disease mediated by alpha-1 antitrypsin deficiency
PT217143452T PT4106757T (en) 2020-04-16 2021-03-16 Methods involving neutrophil elastase inhibitor alvelestat for treating respiratory disease mediated by alpha-1 antitrypsin deficiency
MX2022012942A MX2022012942A (en) 2020-04-16 2021-03-16 Methods involving neutrophil elastase inhibitor alvelestat for treating respiratory disease mediated by alpha-1 antitrypsin deficiency.
FIEP21714345.2T FI4106757T3 (en) 2020-04-16 2021-03-16 Methods involving neutrophil elastase inhibitor alvelestat for treating respiratory disease mediated by alpha-1 antitrypsin deficiency
IL297211A IL297211A (en) 2020-04-16 2021-03-16 Methods involving neutrophil elastase inhibitor alvelestat for treating respiratory disease mediated by alpha-1 antitrypsin deficiency
JP2022562608A JP2023522010A (en) 2020-04-16 2021-03-16 Methods Relating to the Neutrophil Elastase Inhibitor Alberestat for the Treatment of Respiratory Diseases Mediated by Deficiency of α1-Antitrypsin
DK21714345.2T DK4106757T3 (en) 2020-04-16 2021-03-16 METHODS INVOLVING THE NEUTROPHIL ELASTASE INHIBITOR ALVELESTAT FOR THE TREATMENT OF AIRWAY DISEASE MEDIATED BY ALPHA-1-ANTITRYPSIN DEFICIENCY

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB2005520.8A GB202005520D0 (en) 2020-04-16 2020-04-16 Elastase inhibition

Publications (1)

Publication Number Publication Date
GB202005520D0 true GB202005520D0 (en) 2020-06-03

Family

ID=70860131

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB2005520.8A Ceased GB202005520D0 (en) 2020-04-16 2020-04-16 Elastase inhibition

Country Status (1)

Country Link
GB (1) GB202005520D0 (en)

Similar Documents

Publication Publication Date Title
GB201905265D0 (en) Inflammasome inhibition
CA198806S (en) Showerhead
IL290087A (en) Inhibitor compounds
IL289764A (en) Plasma kallikrein inhibitors
GB201914860D0 (en) Inhibitor compounds
CA197078S (en) Showerhead
EP3814324A4 (en) Cathepsin c inhibitors
GB202005520D0 (en) Elastase inhibition
GB202005519D0 (en) Elastase inhibition
EP4117657A4 (en) Viral inhibition
CA198808S (en) Showerhead
GB201905372D0 (en) Elastase inhibition
GB201809937D0 (en) Elastase Inhibition
GB202107909D0 (en) Inhibitory compounds
GB202107783D0 (en) Inhibitory compounds
GB202015998D0 (en) Inhibitory compounds
GB202015985D0 (en) Inhibitory compounds
GB202015820D0 (en) Inhibitory compounds
GB202015832D0 (en) Inhibitory compounds
GB202015802D0 (en) Inhibitory compounds
GB202015692D0 (en) Inhibitory compounds
CA211063S (en) Showerhead
CA211062S (en) Showerhead
CA204986S (en) Showerhead
GB201905370D0 (en) Elastate inhibition

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)